Cemiplimab (Libtayo®) in combination with platinum‐based chemotherapy for the first‐line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Update June 2023

Rothschedl, E. and Wolf, S. (2023): Cemiplimab (Libtayo®) in combination with platinum‐based chemotherapy for the first‐line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Update June 2023. Fact Sheet Nr. 128.

[thumbnail of Fact Sheet Nr.128_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
142kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WF Respiratory system
Language:	English
Series Name:	Fact Sheet Nr. 128
Deposited on:	07 Apr 2023 10:54
Last Modified:	28 Jun 2023 14:35

Repository Staff Only: item control page